Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Primers 7, 33 (2021).
Aisen, P. S. et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res. Ther. 9, 60 (2017).
Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).
Raskin, J., Cummings, J., Hardy, J., Schuh, K. & Dean, R. A. Neurobiology of Alzheimer’s disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr. Alzheimer Res. 12, 712–722 (2015).
Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128 (2010).
Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804 (2012).
Fortea, J. et al. Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet 395, 1988–1997 (2020).
Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 13, 614–629 (2014).
Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305–2316 (2017).
Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381–2387 (2022).
Aisen, P. S., Jimenez-Maggiora, G. A., Rafii, M. S., Walter, S. & Raman, R. Early-stage Alzheimer disease: getting trial-ready. Nat. Rev. Neurol. 18, 389–399 (2022).
US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Early Alzheimer’s Disease: Developing Drugs for Treatment https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alzheimers-disease-developing-drugs-treatment-guidance-industy (2018).
Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275–1283 (2010).
Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446–452 (2006).
Jack, C. R. Jr et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain 131, 665–680 (2008).
De Meyer, G. et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949–956 (2010).
Arriagada, P. V., Marzloff, K. & Hyman, B. T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 42, 1681–1688 (1992).
Morris, J. C. et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 46, 707–719 (1996).
Villemagne, V. L. et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia 46, 1688–1697 (2008).
Stonnington, C. M. et al. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement. 10, e1–e8 (2014).
Moonis, M. et al. Familial Alzheimer disease: decreases in CSF Aβ42 levels precede cognitive decline. Neurology 65, 323–325 (2005).
Klunk, W. E. et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27, 6174–6184 (2007).
Ringman, J. M. et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85–92 (2008).
Reiman, E. M. et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc. Natl Acad. Sci. USA 106, 6820–6825 (2009).
Boerwinkle, A. H. et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 22, 55–65 (2023).
Pike, K. E. et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 130, 2837–2844 (2007).
Wirth, M. et al. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement. 9, 687–698 (2013).
Mormino, E. C. et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71, 1379–1385 (2014).
Lim, Y. Y. et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain 137, 221–231 (2014).
Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578–586 (2012).
Storandt, M., Mintun, M. A., Head, D. & Morris, J. C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Aβ deposition. Arch. Neurol. 66, 1476–1481 (2009).
Pietrzak, R. H. et al. Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol. Aging 36, 1231–1238 (2015).
Jicha, G. A. et al. Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol. Aging 33, 622.e1–622.e16 (2012).
Vos, S. J. et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12, 957–965 (2013).
Knopman, D. S. et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78, 1576–1582 (2012).
Toledo, J. B. et al. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 127, 621–632 (2014).
Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253–260 (2014).
de Graaf, G., Buckley, F. & Skotko, B. G. Estimation of the number of people with Down syndrome in the United States. Genet. Med. 19, 439–447 (2017).
Rafii, M. S., Wishnek, H. & Brewer, J. B. The Down Syndrome Biomarker Initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in Down syndrome. Front. Behav. Neurosci. 9, 239 (2015).
Neale, N., Padilla, C., Fonseca, L. M., Holland, T. & Zaman, S. Neuroimaging and other modalities to assess Alzheimer’s disease in Down syndrome. NeuroImage Clin. 17, 263–271 (2018).
Handen, B. L., Cohen, A. D. & Channamalappa, U. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 8, 496–501 (2012).
Annus, T., Wilson, L. R. & Hong, Y. T. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 12, 538–545 (2016).
Lao, P. J., Betthauser, T. J. & Hillmer, A. T. The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement. 12, 380–390 (2016).
Fortea, J. et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 17, 860–869 (2018).
Fleisher, A. S., Chen, K. & Quiroz, Y. T. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 72, 316–324 (2015).
Rafii, M. S. et al. A randomized, double-blind, placebo-controlled, phase II study of oral ELND005 (scyllo-inositol) in young adults with Down syndrome without dementia. J. Alzheimers Dis. 58, 401–411 (2017).
Rafii, M. S. et al. Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with Down syndrome: a phase 1b randomized clinical trial. JAMA Neurol. 79, 565–574 (2022).
Rafii, M. S. Alzheimer’s disease in Down syndrome: progress in the design and conduct of drug prevention trials. CNS Drugs 34, 785–794 (2020).
Jack, C. R. Jr et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).
Knopman, D. S. et al. The National Institute on Aging and the Alzheimer’s Association Research Framework for Alzheimer’s disease: perspectives from the Research Roundtable. Alzheimers Dement. 14, 563–575 (2018).
Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 79, 975–985 (2022).
van der Flier, W. M. & Scheltens, P. The ATN framework—moving preclinical Alzheimer disease to clinical relevance. JAMA Neurol. 79, 968–970 (2022).
Soldan, A. et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology 92, e1567–e1579 (2019).
Vos, S. J. B. & Duara, R. The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals. Neurology 92, 643–644 (2019).
Delmotte, K. et al. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease. Alzheimers Res. Ther. 13, 84 (2021).
Allegri, R. F. et al. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 12, e12026 (2020).
Selvackadunco, S. et al. Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. J. Neural Transm. 126, 327–337 (2019).
Morris, J. C. et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66, 1469–1475 (2009).
Vemuri, P. et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73, 294–301 (2009).
Fagan, A. M. et al. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65, 176–183 (2009).
Lowe, V. J. et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 82, 1959–1967 (2014).
Nettiksimmons, J. et al. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol. Aging 31, 1419–1428 (2010).
Pankratz, V. S. et al. Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology 84, 1433–1442 (2015).
Stomrud, E. et al. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch. Neurol. 67, 217–223 (2010).
Sutphen, C. L. et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 72, 1029–1042 (2015).
Dumurgier, J. et al. Alzheimer’s disease biomarkers and future decline in cognitive normal older adults. J. Alzheimers Dis. 60, 1451–1459 (2017).
Farrell, M. E. et al. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology 96, e619–e631 (2021).
Campbell, M. R. et al. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement. 13, e12190 (2021).
Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823–e1834 (2021).
Bourgeat, P. et al. β-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 74, 121–127 (2010).
Oh, H. et al. β-amyloid affects frontal and posterior brain networks in normal aging. NeuroImage 54, 1887–1895 (2011).
Dickerson, B. C. et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 19, 497–510 (2009).
Sperling, R. A. et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178–188 (2009).
Hedden, T. et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 29, 12686–12694 (2009).
Mormino, E. C. et al. Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb. Cortex 21, 2399–2407 (2011).
Rentz, D. M. et al. Face–name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 49, 2776–2783 (2011).
Chetelat, G. et al. Independent contribution of temporal β-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer’s disease. Brain 134, 798–807 (2011).
Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).
Schindler, S. E. et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, e1647–e1659 (2019).
Li, Y. et al. Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques. Neurology 98, e688–e699 (2022).
Fandos, N. et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement. 8, 179–187 (2017).
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).
Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989–997 (2018).
Janelidze, S. et al. Plasma p-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med. 26, 379–386 (2020).
Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol. 76, 1060–1069 (2019).
Cullen, N. C. et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat. Commun. 12, 3555 (2021).
Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961–971 (2021).
Rafii, M. S. et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer’s disease. Alzheimers Dement. https://doi.org/10.1002/alz.12748 (2022).
Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110–119 (2016).
Insel, P. S. et al. Tau positron emission tomography in preclinical Alzheimer’s disease. Brain 146, 700–711 (2023).
Mattsson-Carlgren, N. et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 80, 360–369 (2023).
Mosconi, L. et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 29, 676–692 (2008).
Kennedy, A. M. et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neurosci. Lett. 186, 17–20 (1995).
de Leon, M. J. et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl Acad. Sci. USA 98, 10966–10971 (2001).
Jagust, W. J. et al. Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann. Neurol. 59, 673–681 (2006).
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F. & Cash, D. Imaging synaptic density: the next holy grail of neuroscience? Front. Neurosci. 16, 796129 (2022).
Mecca, A. P. et al. In vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET. Alzheimers Dement. 16, 974–982 (2020).
Arvidsson Rådestig, M. et al. Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample. Alzheimers Res. Ther. 15, 44 (2023).
Zetterberg, H. et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 73, 60–67 (2016).
Ferreira, P. C. L. et al. Plasma biomarkers identify older adults at risk of Alzheimer’s disease and related dementias in a real-world population-based cohort. Alzheimers Dement. https://doi.org/10.1002/alz.12986 (2023).
Pettigrew, C. et al. Progressive medial temporal lobe atrophy during preclinical Alzheimer’s disease. NeuroImage Clin. 16, 439–446 (2017).
Pettigrew, C. et al. Cortical thickness in relation to clinical symptom onset in preclinical AD. NeuroImage Clin. 12, 116–122 (2016).
Mueller, S. G. et al. Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer’s disease. Hum. Brain Mapp. 31, 1339–1347 (2010).
McRae-McKee, K. et al. Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals. Sci. Rep. 9, 7499 (2019).
Elias, M. F. et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch. Neurol. 57, 808–813 (2000).
Saxton, J. et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 63, 2341–2347 (2004).
Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961–970 (2014).
Bransby, L. et al. Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s disease. J. Clin. Exp. Neuropsychol. 41, 591–600 (2019).
Papp, K. V. et al. Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to amyloid status in preclinical Alzheimer’s disease—Atabecestat Phase 2b/3 EARLY Clinical Trial. J. Prev. Alzheimers Dis. 9, 255–261 (2022).
Ayutyanont, N. et al. The Alzheimer’s Prevention Initiative Composite Cognitive Test score: sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. J. Clin. Psychiatry 75, 652–660 (2014).
Langbaum, J. B. et al. The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease. Alzheimers Res. Ther. 12, 66 (2020).
Amariglio, R. E. et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer’s Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 72, 446–454 (2015).
Li, C. et al. The utility of the Cognitive Function Instrument (CFI) to detect cognitive decline in non-demented older adults. J. Alzheimers Dis. 60, 427–437 (2017).
Galasko, D. et al. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis. Assoc. Disord. 20, S152–S169 (2006).
Marshall, G. A. et al. Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimers Res. Ther. 11, 4 (2019).
Weintraub, S. et al. Measuring cognition and function in the preclinical stage of Alzheimer’s disease. Alzheimers Dement. 4, 64–75 (2018).
Barnes, D. E. & Yaffe, K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 10, 819–828 (2011).
Ding, J. et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 19, 61–70 (2020).
Marinelli, J. P. et al. Association between hearing loss and development of dementia using formal behavioural audiometric testing within the Mayo Clinic Study of Aging (MCSA): a prospective population-based study. Lancet Healthy Longev. 3, e817–e824 (2022).
Middleton, L. E., Barnes, D. E., Lui, L. Y. & Yaffe, K. Physical activity over the life course and its association with cognitive performance and impairment in old age. J. Am. Geriatr. Soc. 58, 1322–1326 (2010).
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V. & Pelidou, S. H. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines 7, 97 (2019).
Arndt, J. W. et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep. 8, 6412 (2018).
Ferrero, J. et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement. 2, 169–176 (2016).
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 9, 197–210 (2022).
Ostrowitzki, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198–207 (2012).
Klein, G. et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res. Ther. 11, 101 (2019).
Doody, R. Clinical Trial in Alzheimer’s Disease (CTAD) meeting, November 29 (2022).
Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat. Med. 27, 1187–1196 (2021).
Lowe, S. L. et al. Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J. Prev. Alzheimers Dis. 8, 414–424 (2021).
Mintun, M. A. et al. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 384, 1691–1704 (2021).
Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).
van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).
Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367–385 (2011).
Barakos, J. et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid β therapy. J. Prev. Alzheimers Dis. 9, 211–220 (2022).
Piazza, F. et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann. Neurol. 73, 449–458 (2013).
Salloway, S. et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79, 13–21 (2022).
Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 311–321 (2014).
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
Lilly. Lilly provides update on A4 study of solanezumab for preclinical Alzheimer’s disease. investory.lilly.com, https://investor.lilly.com/news-releases/news-release-details/lilly-provides-update-a4-study-solanezumab-preclinical#:~:text=INDIANAPOLIS%2C%20March%208%2C%202023%20%2FPRNewswire%2F%20–%20Eli%20Lilly,known%20as%20the%20preclinical%20stage%20of%20AD%201 (8 March 2023).
Vassar, R. et al. β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).
Jonsson, T. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99 (2012).
Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N. Engl. J. Med. 380, 1408–1420 (2019).
Henley, D. et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N. Engl. J. Med. 380, 1483–1485 (2019).
Wessels, A. M. et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 77, 199–209 (2019).
Sperling, R. et al. Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b/3 clinical trial. JAMA Neurol. 78, 293–301 (2021).
McDade, E. et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat. Rev. Neurol. 17, 703–714 (2021).
Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399–415 (2018).
Langbaum, J. B. et al. Recommendations to address key recruitment challenges of Alzheimer’s disease clinical trials. Alzheimers Dement. 19, 696–707 (2023).
Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess DiTerlizzi, C. & Jackson, J. Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in Alzheimer’s disease research. J. Alzheimers Dis. 80, 927–940 (2021).
Aisen, P. S. et al. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) project: an overview. J. Prev. Alzheimer’s Dis. 7, 208–212 (2020).
Aisen, P. S. et al. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) project: an overview. J. Prev. Alzheimers Dis. 7, 208–212 (2020).